Rise and Fall: Hydroxychloroquine and COVID‐19 Global Trends: Interest, Political Influence, and Potential Implications
Open accessAbstract
Objective: The coronavirus disease 2019 (COVID‐19) pandemic has led to rapid research and reporting on potential preventatives and treatments for the disease, including the drug hydroxychloroquine (HCQ). Despite a lack of robust evidence to support the use of HCQ for treatment of COVID‐19, it was publicly endorsed and received widespread media coverage and public interest. The purpose of this report is to describe and contextualize the surges in public interest, demand, and adoption of HCQ for treatment of COVID‐19 and outline implications for future public health policy and practice. Methods: Using national and global events and Google Trends data as a measure of public interest, we describe the timeline and trends in the emergence of, interest in, and adoption of HCQ as a treatment of COVID‐19. We additionally review reports on public demand for HCQ for treatment of COVID‐19 and impacts on medication access among patients with indicated uses. Results: Public interest and demand for HCQ surged in the United States and globally following endorsements from public officials and enaction of policies to facilitate off‐label use of HCQ for treatment of COVID‐19. Surges in demand for HCQ led to multiple documented shortages and barriers to accessing HCQ treatment for patients with indicated uses for HCQ. Although there have been reversals in policies to support HCQ use for treatment of COVID‐19 in some regions, others have continued or expanded recommended uses. Conclusion: Insights from the global response to HCQ and COVID‐19 can be used to inform prudent decision‐making in the future to prevent premature action and promote informed and equitable responses to promote public health.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Adoption of HCQ as a treatment for COVID-19 created increased interest and demand in the United States and globally, resulting in shortages and other reported barriers impacting patients' access to HCQ.
“Specifically, the adoption of hydroxychloroquine (HCQ) as a treatment for COVID‐19 created increased interest and demand in the United States and globally (4), resulting in shortages and other reported barriers impacting patients’ access to HCQ.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Gautret, P., Lagier, J., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Esteves-Vieira, V., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288 · see citing works
RetractedInternational Norm Dynamics and Political Change
Finnemore, M., & Sikkink, K. (1998) · International Organization · doi:10.1162/002081898550789 · Cited by 8,292 · see citing works
WHO Coronavirus Disease (COVID-19) Dashboard
(2020) · Bangladesh Physiotherapy Journal · doi:10.46945/bpj.10.1.03.01 · Cited by 5,545 · see citing works
The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States
Tai, D. B. G., Shah, A., Doubeni, C. A., Sia, I. G., & Wieland, M. L. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa815 · Cited by 1,390 · see citing works
The political origins of health inequity: prospects for change
Ottersen, O. P., Dasgupta, J., Blouin, C., Buss, P., Chongsuvivatwong, V., Frenk, J., Fukuda-Parr, S., Gawanas, B. P., Giacaman, R., Gyapong, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62407-1 · Cited by 683 · see citing works
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19
Skipper, C. P., Pastick, K. A., Engen, N. W., Bangdiwala, A. S., Abassi, M., Lofgren, S. M., Williams, D. A., Okafor, E. C., Pullen, M. F., Nicol, M. R., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-4207 · Cited by 538 · see citing works
Pulido, C., Villarejo-Carballido, B., Redondo-Sama, G., & Gómez, A. (2020) · International Sociology · doi:10.1177/0268580920914755 · Cited by 449 · see citing works
Kim, A. H. J., Sparks, J. A., Liew, J. W., Putman, M., Berenbaum, F., Duarte‐García, A., Graef, E. R., Korsten, P., Sattui, S. E., Sirotich, E., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1223 · Cited by 206 · see citing works
Michaud, K. D., Wipfler, K., Shaw, Y., Simon, T. A., Cornish, A., England, B. R., Ogdie, A., & Katz, P. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11148 · Cited by 164 · see citing works
Higgins, T. S., Wu, A. W., Sharma, D., Illing, E. A., Rubel, K., Ting, J. Y., & Snot Force Alliance (2020) · JMIR Public Health and Surveillance · doi:10.2196/19702 · Cited by 129 · see citing works
Shin, S.-Y., Seo, D., An, J., Kwak, H., Kim, S., Gwack, J., & Jo, M. (2016) · Scientific Reports · doi:10.1038/srep32920 · Cited by 124 · see citing works
Hydroxychloroquine prophylaxis for COVID-19 contacts in India
Rathi, S., Ish, P., Kalantri, A., & Kalantri, S. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30313-3 · Cited by 120 · see citing works
Internet Searches for Unproven COVID-19 Therapies in the United States
Liu, M., Caputi, T. L., Dredze, M. H., Kesselheim, A. S., & Ayers, J. W. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.1764 · Cited by 117 · see citing works
Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence
Lenzer, J. (2020) · BMJ · doi:10.1136/bmj.m1335 · Cited by 115 · see citing works
Ensuring Access to Medications in the US During the COVID-19 Pandemic
Alexander, G. C., & Qato, D. M. (2020) · JAMA · doi:10.1001/jama.2020.6016 · Cited by 94 · see citing works
Drenkard, C., & Lim, S. S. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000646 · Cited by 88 · see citing works
Bull–Otterson, L., Gray, E. B., Budnitz, D. S., Strosnider, H. M., Schieber, L. Z., Courtney, J. G., García, M. C., Brooks, J. T., Kenzie, W. R. M., & Gundlapalli, A. V. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6935a4 · Cited by 73 · see citing works
Sattui, S. E., Liew, J. W., Graef, E. R., Coler-Reilly, A. L. G., Berenbaum, F., Duarte‐García, A., Harrison, C., Konig, M. F., Korsten, P., Putman, M., et al. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1792778 · Cited by 66 · see citing works
The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study
Ziadé, N., Hmamouchi, I., Kibbi, L. E., Abdulateef, N., Halabi, H. M., Abutiban, F., Hamdi, W., Rakawi, M. E., Eissa, M., & Masri, B. K. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05428-2 · Cited by 57 · see citing works
Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
Hernández, A. V., Roman, Y. M., Pasupuleti, V., Barboza, J. J., & White, C. M. (2020) · Annals of Internal Medicine · doi:10.7326/l20-0945 · Cited by 46 · see citing works
Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine
Aouhab, Z., Hong, H., Felicelli, C., Tarplin, S., & Ostrowski, R. A. (2019) · ACR Open Rheumatology · doi:10.1002/acr2.11084 · Cited by 37 · see citing works
Hydroxychloroquine shortages during the COVID-19 pandemic
Mendel, A., Bernatsky, S., Thorne, C., Lacaille, D. V., Johnson, S. R., & Vinet, É. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217835 · Cited by 37 · see citing works
Offline: A global health crisis? No, something far worse
Horton, R. C. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31017-5 · Cited by 32 · see citing works
Using search engine query data to track pharmaceutical utilization: a study of statins.
Schuster, N. M., Rogers, M. A. M., & McMahon, L. F. (2010) · PubMed · Cited by 29 · see citing works
Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
Hernández, A. V., Roman, Y. M., Pasupuleti, V., Barboza, J. J., & White, C. M. (2020) · Annals of Internal Medicine · doi:10.7326/l20-1257 · Cited by 27 · see citing works
Simmering, J. E., Polgreen, L. A., & Polgreen, P. M. (2014) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2014.01.003 · Cited by 26 · see citing works
Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
Hernández, A. V., Roman, Y. M., Pasupuleti, V., Barboza, J. J., & White, C. M. (2020) · Annals of Internal Medicine · doi:10.7326/l20-1054 · Cited by 23 · see citing works
Addis, A., Genazzani, A. A., Trotta, M. P., & Magrini, N. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3775 · Cited by 16 · see citing works
The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale
Schluger, N. W. (2020) · Annals of Internal Medicine · doi:10.7326/m20-5041 · Cited by 16 · see citing works
Chloroquine and COVID-19, where do we stand?
Lecuit, M. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.004 · Cited by 14 · see citing works
What we need is a sustainable politics of life
Sandset, T. J., Heggen, K. M., & Engebretsen, E. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31378-7 · Cited by 6 · see citing works
Digital Pathways, Pandemic Trajectories. Using Google Trends to Track Social Responses to COVID-19Preprint
Beytía, P., & Infante, C. C. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3571360 · Cited by 4 · see citing works
Hydroxychloroquine side-effects raise concerns for rheumatology patients
Owens, B. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30184-3 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Methodology over metrics: current scientific standards are a disservice to patients and society
Van Calster, B., Wynants, L., Riley, R. D., van Smeden, M., & Collins, G. S. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.05.018 · Cited by 105 · see citing works
Google Trends as a predictive tool in the era of COVID-19: a scoping review
Zayed, B. A., Talaia, A. M., Gaaboobah, M. A., Amer, S. M., & Mansour, F. R. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad012 · Cited by 16 · see citing works
Global interest in vaccines during the COVID‐19 pandemic: Evidence from Google Trends
Khakimova, A. K., Abdollahi, L., Золотарев, О., & Rahim, F. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100152 · Cited by 14 · see citing works
Sinharoy, A., Pal, S., Das, J. K., & Mondal, P. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.687864 · Cited by 6 · see citing works
Rockwell, M. S., Vangala, S., Hadfield, M., Cantor, J., Skinner, D., Craff, M., Fendrick, A. M., Damberg, C. L., Kahn, K. L., & Mafi, J. N. (2025) · Health Affairs · doi:10.1377/hlthaff.2024.00452 · Cited by 5 · see citing works
Ho, M. K. H., Tadrous, M., Iacono, A., Suda, K. J., & Gomes, T. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac382 · Cited by 6 · see citing works
McCormick, E. M., Englund, T. R., Cleveland, R. J., Dickson, T. A., Schiller, C. E., & Sheikh, S. Z. (2022) · ACR Open Rheumatology · doi:10.1002/acr2.11433 · Cited by 5 · see citing works
“19 pandemic–specific concerns related to medication access, namely HCQ (4), we sought to assess whether our patients had been impacted by these disruptions and shortages.”
BackgroundInfluentialSelf-citationSaxena, S., Dickson, T. A., Englund, T. R., Cleveland, R. J., McCormick, E. M., Santana, A. E., Walker, J. A., Allen, K. D., & Sheikh, S. Z. (2022) · ACR Open Rheumatology · doi:10.1002/acr2.11507 · Cited by 4 · see citing works
Self-citationTextEssence: A Tool for Interactive Analysis of Semantic Shifts Between Corpora
Newman-Griffis, D. R., Sivaraman, V., Perer, A., Fosler‐Lussier, E., & Hochheiser, H. (2021) · doi:10.18653/v1/2021.naacl-demos.13 · Cited by 3 · see citing works
Ferorelli, D., Spagnolo, L., Marrone, M., Corradi, S., Silvestre, M. E. A., Misceo, F., Bianchi, F. P., Stefanizzi, P., Solarino, B., Dell'Erba, A. S., et al. (2021) · Vaccines · doi:10.3390/vaccines9050423 · Cited by 3 · see citing works
Dickinson, R., Makowski, D., van Marwijk, H., & Ford, E. M. (2024) · COVID · doi:10.3390/covid4120132 · Cited by 1 · see citing works
A temporal cluster of cutaneous drug eruptions developing after initiation of hydroxychloroquine
Jadeja, S., Temiz, L. A., Dewan, A., & Parker, E. R. (2022) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2021.2024018 · Cited by 1 · see citing works
Kane, P. B., Moyer, H., MacPherson, A., Papenburg, J., Ward, B. J., Broomell, S. B., & Kimmelman, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262740
Multispecies Solidarity: How People and Cinchona Survived the COVID ‐19 Pandemic in Loja, Ecuador
McNamara, K. (2025) · Culture Agriculture Food and Environment · doi:10.1111/cuag.70011
- Authors
- Englund, T. R., Kinlaw, A. C., & Sheikh, S. Z.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Sheikh, Saira Z.
- Venue
- ACR Open Rheumatology
- Publisher
- Wiley
- Published
- 2020-12
- Volume
- 2
- Issue
- 12
- Pages
- 760-766
- ISSN
- 2578-5745 (ISSN-L)
- PMC
- PMC7738805
- OpenAlex
- W3107997132
- Cited by
- 15
- References
- 33
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2022: 6 · 2021: 5
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- ACR Open Rheumatology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- UNC Libraries
- Funders
- Pfizer
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Epidemiology › Data-Driven Disease Surveillance
- Social Sciences › Sociology and Political Science › Misinformation and Its Impacts
- Keywords
- hydroxychloroquine, COVID-19 pandemic, public interest, media coverage, off-label drug use, drug shortages, access to medicines, political influence on medicine, public health policy, Google Trends, drug repurposing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
